Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals orders, deals and press releases
594 filed, newest first. Page 10 of 12.
May 2011
4 May · Business
Board of Directors of the Company at its Operations Committee Meeting held on May 04, 2011 allotted 47,150 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Apr 2011
Mar 2011
18 Mar · Business
Board of Directors of the Company at its Operations Committee Meeting held on March 18, 2011 allotted 10,350 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Feb 2011
16 Feb · Business
Board of Directors of the Company at its Operations Committee Meeting held on February 15, 2011 allotted 55,100 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Jan 2011
24 Jan · Business
Board of Directors of the Company, at its Operations Committee Meeting held on January 21, 2011 allotted 37,900 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Dec 2010
20 Dec · Business
Board of Directors of the Company, at its Operations Committee Meeting held on December 20, 2010 allotted 24,500 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Nov 2010
19 Nov · Business
Board of Directors of the Company, at its Operations Committee Meeting held on November 19, 2010 allotted 63,200 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Oct 2010
27 Oct · Business
Board of Directors of the Company, at its Board Meeting held on October 27, 2010 allotted 37,350 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Sep 2010
29 Sep · Business
Board of Directors of the Company, at its Operations Committee Meeting held on September 27, 2010 allotted 29,200 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2010
25 Aug · Business
Board of Directors of the Company, at its Operations Committee Meeting held on August 24, 2010 allotted 38,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.10 Aug · Business
Board of Directors of the Company, at its Meeting held on August 09, 2010 allotted 62,300 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jul 2010
12 Jul · Business
Board of Directors of the Company, at its Operations Committee Meeting held today i.e. on July 10, 2010 allotted 7,400 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jun 2010
May 2010
10 May · Business
Board of Directors of the Company, at its Operations Committee Meeting held on May 10, 2010 allotted 21,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.